Rapid Delivery of Therapy to the Macula using Novel Suprachoroidal Delivery Technology
Time: 9:00 am
day: Conference Day Two
Details:
- Achieving rapid and extensive coverage of the posterior coverage in non-human primates and pigs leveraging a novel delivery technology
- Compatibility and experience with gene therapy, demonstrating AAV-GFP expression at the macula in various non-human primate studies up to 85 days post injection
- Update on first-in-human clinical trial using Everads’ suprachoroidal delivery technology
